Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

ATTR-CM often requires a team of healthcare providers, including cardiologists, specialists, and primary care doctors. Caregivers play an important role in coordinating appointments, sharing ...

Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup analyses from the ATTRibute-CM and HELIOS ...

Is rhythm control underused in ATTR-CM? Drs Kevin Alexander and Ronald Witteles make the case for rethinking how we manage arrhythmias in this disease. Is rhythm control underused in ATTR-CM? Drs ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it has entered into strategic collaborations with Viz.ai and the American Heart Association to improve the detection and care management of patients ...

Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of therapy and exposure up to 58 months. Exposure-adjusted overall and serious ...

Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies. This episode, titled ‘Navigating Benefit Design and Utilization ...

Google Chrome and other Chromium-based browsers, including Edge and Vivaldi, could soon get native support for video and ...